Trials / Completed
CompletedNCT03286296
LZM009 to Treat Patients With Advanced Solid Tumors
A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation Study of LZM009 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Livzon Pharmaceutical Group Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of IV administered LZM009 in subjects with advanced solid tumors who have progressed or are non-responsive to available therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection | LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study |
Timeline
- Start date
- 2017-08-21
- Primary completion
- 2019-03-06
- Completion
- 2019-04-23
- First posted
- 2017-09-18
- Last updated
- 2019-08-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03286296. Inclusion in this directory is not an endorsement.